[en] Background : The incidence and severity of herpes zoster (HZ) appear increased in patients receiving tumor necrosis factor-alpha antagonists. Objective : To study the incidence and clinical features of HZ in 1,220 patients (4.206 patient-years) receiving either adalimumab, etanercept, infliximumab, rituximab or ustekinumab. Results: Twenty-two HZ cases were identified (1.26% of total cohort; adalimumab: 11/1,546 patient-years, incidence rate (IR) 7.1; etanercept: 4/789 patient-years, IR5.1; rituximab: 1/168 patient-years, IR 5.2; ustekinumab: 2/37 patient-years, IR53.5; infliximab: 4/1.666 patient-years, IR 2.4). The time to event varied widely (1.5-108 months). Extensive HZ was reported in 45 and 32% of the cases, respectively. Persistent postzoster neuralgia (PHN;>6months) was observed in 5/20 patients. Conclusions: The Hz incidence was 2.1-fold higher among patients over 60 years, compared with a reference population, although not statistically significant. Severe, multidermatomal HZ and persistent PHN were common.